Yescarta (axicabtagene ciloleucel) / Cabaret Biotech, National Cancer Institute, Gilead, Fosun Kite - LARVOL DELTA

Assessing the risk of cytokine release syndrome associated with the use of antineoplastic agents: A real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database (FAERS). (ASCO 2025) - " Among the top 10 drugs associated with CRS, CAR-T therapies exhibited the strongest disproportionality signals, with Axicabtagene Ciloleucel (ROR: 1946.596, PRR: 1104.019), Tisagenlecleucel (ROR: 1541.613, PRR: 908.159), and Brexucabtagene Autoleucel (ROR: 1385.781, PRR: 815.937) ranking highest...Blinatumomab (ROR: 216.203, PRR: 195.902), a BiTE therapy, ranked fourth, reflecting a moderate but significant CRS signal. Fludarabine (ROR: 128.879, PRR: 121.137), an immunosuppressive agent used in lymphodepleting regimens before CAR-T therapy, also exhibited a notable CRS association, likely due to its role in enhancing immune cell expansion. Traditional chemotherapy agents demonstrated lower CRS signals, with Cyclophosphamide (ROR: 26.215, PRR: 25.886) and monoclonal antibody Rituximab (ROR: 6.973, PRR: 6.952) showing relatively modest disproportionality. Corticosteroids, which are commonly used to mitigate CRS symptoms, had the lowest disproportionality signals, with..."

Adverse events • Clinical • Cytokine release syndrome • Real-world • Real-world evidence • Inflammation • Oncology

A Cost-Effectiveness Analysis of Diffuse Large B-Cell Lymphoma Treatment Pathways in the United States. (PubMed, MDM Policy Pract) - "Simulated patients received 2L axi-cel followed by 3L treatments, which were compared with treatment sequences of 2L intended autologous stem cell transplant (ASCT), polatuzumab vedotin with bendamustine and rituximab (Pola-BR), tafasitamab with lenalidomide (tafa-len), or rituximab with gemcitabine and oxaliplatin (R-GemOx), all of which were followed by 3L treatments (salvage chemotherapy, BsAbs, or axi-cel). In addition, axi-cel was compared directly with glofitamab and epcoritamab in 3L...The findings of the study suggest that although other treatments were cost-effective at lower thresholds, axi-cel is a cost-effective treatment option in 2L/3L settings in the United States. This study investigated whether axicabtagene ciloleucel (axi-cel) is cost-effective in second-line (2L) and third-line (3L) treatment sequences in the current relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) treatment paradigm.Using a novel treatment sequencing model, axi-cel..."

HEOR • Journal • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Transplantation

POLATUZUMAB-CONTAINING REGIMENS AS BRIDGE TO CAR-T: INSIGHTS FROM THE ITALIAN CAR T-SIE STUDY (ICML 2025) - "Polatuzumab vedotin (PV) combined with rituximab (R) ± bendamustine (BR) is effective in LBCL relapsed/refractory to at least a previous line of therapy, being promising for candidates for CART... This multicenter, observational, retrospective study was conducted on the Italian CART-SIE study, including patients diagnosed with refractory or relapsed LBCL and treated with commercial anti-CD19 CART (axi-cel, tisa-cel, liso-cel)... In this multicenter, retrospective study PV-R and PV-BR were efficacious in controlling the tumor prior to CART, with similar responses and immune cell-associated toxicities after infusion. The higher incidence of hematological toxicities in the PV-BR group, combined with the resulting potential delay in CART infusion highlights the PV-R regimen as the treatment of choice, paving the way for a chemo-sparing regimen as a bridge to CART."

B Cell Lymphoma • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma

Evaluating peripheral eosinophilia as a biomarker post CAR-T cell therapy. (ASCO 2025) - " This multicenter, retrospective study used TriNetX database to analyze patients with B-cell lymphoma who had received CD19 CAR-T cell therapies—Liso-Cel, Axi-Cel, Brexu-Cel, or Tisa-Cel—and developed eosinophilia (>500/µL) within first month after CAR T-cell administration (Cohort 1) vs those who didn't develop eosinophilia (Cohort 2).The outcomes of interest were the risk of CRS, ICANS, late ICAHT (after day 30), and risk of infection (after day 30) after CAR-T therapy administration. This study suggests that absence of peripheral eosinophilia may identify patients at higher risk for CRS, ICANS and late ICAHT. The potential explanation for this could be that eosinophils act as potent immune effectors and immune modulators in the tumor microenvironment post-CAR-T cell therapy. These findings could guide decisions on monitoring and administration of alternative therapies."

Biomarker • CAR T-Cell Therapy • IO biomarker • Anemia • B Cell Lymphoma • Eosinophilia • Hematological Malignancies • Infectious Disease • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Thrombocytopenia

BRIDGING RADIATION THERAPY IN CAR-T THERAPY (ICML 2025) - "Patients received various CD-19 directed CAR T constructs (consisting of tisagenlecleucel, axicabtagene ciloleucel or our in-house academic CD-19 directed CAR-T product). Bridging RT shows efficacy and safety for patients undergoing CAR T therapy. Further areas for optimization include volume, dose, fractionation and sequencing to improve CAR T outcomes. Ongoing investigation in this area should continue to optimize the utility of bridging RT for patients undergoing CAR T."

B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma

"Real World" Incidence and Characteristics of Immune Effector Cell–Associated Hemophagocytic Lymphohisticytosis: A GoCart Coalition Study on Behalf of the European Bone Marrow Trasplantation (EBMT) Autoimmune Disease Working Party (ADWP), Cellular Therapy Working Party (CTIWP) and transplant Complication Working Party(TCWP). (EULAR 2025) - "Secondary HLH occurred in 12 patients treated with tisagenlecleucel (42.9%), 10 with axicabtagene ciloleucel (35.7%), 4 with brexucabtagene autoleucel (14.3%), and 2 treated with other products (7.2%). Overall, this registry study reported an incidence of 3.6% of secondary HLH at 90 days after CAR-T cell treatment. Patients experienced heterogeneous clinical manifestations, mainly represented by fever and liver involvement. Anakinra and steroids represented the employed treatments and the overall survival was 80.9% at 90 days."

Clinical • IO biomarker • Real-world • Real-world evidence • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • B Cell Lymphoma • Bone Marrow Transplantation • Hematological Malignancies • Immunology • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Transplantation

A MULTI-CENTER REAL-LIFE ANALYSIS ON PATIENTS WITH LARGE B-CELL LYMPHOMA AFTER FAILURE OF CAR-T CELLS THERAPY (ICML 2025) - " Among 241 CAR-T recipients, 119 (61 axi-cel, 58 tisa-cel) relapsed or were refractory...Other therapies included polatuzumab-based regimens (27%), chemotherapy (22%), immunomodulatory agents (15%), radiotherapy (6%) and experimental drugs (11%)... Post-CAR-T relapse in LBCL is associated with poor outcomes. BiAB show the most promise but have been difficult to access. Prognostic factors such as LDH, extranodal involvement, and early relapse can guide therapy."

CAR T-Cell Therapy • Clinical • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

EXPLORING SHORT-TERM PATIENT-REPORTED ADVERSE EVENTS (AES) AND HEALTH-RELATED QUALITY OF LIFE (HRQOL) BY CAR T-CELL PRODUCT IN PATIENTS WITH AGGRESSIVE B-CELL LYMPHOMAS: EVIDENCE FROM A REAL-WORLD STUDY BY THE GIMEMA (EHA 2025) - "All analyses were explorative.Overall, 143 patients were eligible for this analysis, of whom 86, 34 and 23 received axi-cel, tisa-cel and brexu-cel, respectively. Our findings may help to better understand impact of CART-cell products on symptom prevalence and suggest that the type of CART-cell product is not associated with short-term HRQoL. Further research is warranted to elucidate on factors predicting longer-term symptoms and HRQoL outcomes."

Adverse events • CAR T-Cell Therapy • Clinical • HEOR • Real-world • Real-world evidence • Alopecia • Anorexia • B Cell Lymphoma • CNS Disorders • Fatigue • Hematological Malignancies • Insomnia • Lymphoma • Musculoskeletal Diseases • Musculoskeletal Pain • Non-Hodgkin’s Lymphoma • Oncology • Orthopedics • Pain • Sleep Disorder

CAR-T CELLS SPECIFIC TOXICITIES AS MAJOR DETERMINANTS OF NON-RELAPSE MORTALITY: AN ANALYSIS FROM THE ITALIAN CART-SIE STUDY (EHA 2025) - "CAR-T product was Axicabtagene ciloleucel, Brexucabtagene autoleucel or Tisagenlecleucel in 55%, 21% and 24% pts, respectively; median age was 65 yrs (IQR 56-68); 2/47 had received CAR-T at 1st relapse. In our cohort, older age, CRS, ICANS and infections were major determinants of NRM. The stringent Italian Drug Agency eligibility criteria have excluded baseline patients' characteristics that might otherwise affect NRM, highlighting the predominant impact of CAR-T toxicities. While acute complications are usually well-managed, early intervention to prevent and mitigate CRS and ICANS could be furtherly refined to reduce NRM."

CAR T-Cell Therapy • B Cell Lymphoma • Cardiovascular • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Infectious Disease • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma

Safety and efficacy of outpatient CAR-T therapy in a community-based medical center. (ASCO 2025) - "22 patients received treatment with Axi-cel, 6 patients were treated with Liso-cel, and 16 patients received Tisa-cel. 1 Axi-cel patient received prophylactic dexamethasone... This retrospective analysis confirms that outpatient CAR-T therapy can safely be administered in an outpatient community setting anticipated survival. This may allow more patients who cannot travel to receive this treatment. Comparative outcomes between CAR-T therapies."

Clinical • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

T-Cell Redirecting Strategies in Large B-Cell Lymphoma and Follicular Lymphoma (ICML 2025) - "The randomized STARGLO trial compared the combination of glofitamab with gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx, meeting its primary endpoint of OS in favor of the experimental arm (HR 0.62 [95% CI 0.43–0.88])...Other treatment options to consider in this R/R patient population are tafasitamab/lenalidomide [107], loncastuximab tesirine [108] and rituximab-bendamustine-polatuzumab [109], amongst others...Three CAR-T constructs are available based on Phase 2, single-arm trials, namely ZUMA-5 (axi-cel), ELARA (tisa-cel), and TRANSCEND-FL (liso-cel)...Mosunetuzumab, epcoritamab and odronextamab received regulatory approval (U.S...She started treatment with a bispecific antibody, aiming to carry out her first imaging assessment after three cycles. Permission to Reproduce Material From Other Sources The author has nothing to report."

IO biomarker • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Large B Cell Lymphoma • Lymphoma • Mediastinal B Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma • T Cell Histiocyte Rich Large B Cell Lymphoma • T Cell Non-Hodgkin Lymphoma • CD19

HISTOLOGICAL CHARACTERISTICS, TREATMENT PATTERNS, AND OUTCOMES FOLLOWING DISEASE PROGRESSION AFTER CAR-T THERAPY IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (ICML 2025) - "Administered products were axicabtagene ciloleucel (84%), tisagenlecleucel (12%), and lisocabtagene maraleucel (4%), predominantly as SOC (96%)...Administered therapies included CD3×CD20 bispecific antibodies (BsAbs) (n = 10; 8 evaluable, ORR 88%, CR 63%), chemoimmunotherapy (n = 6, ORR 83%, CR 50%), tafasitamab-based combinations (lenalidomide, n = 1; tazemetostat, n = 1; no response), lenalidomide + obinutuzumab (n = 1; no response), and investigational agent (n = 1; ORR 100%)... To our knowledge, this represents the largest cohort of FL pts with POD post-CAR-T. BsAbs showed promise in this setting, but longer follow-up is needed for durability assessment. The mechanisms associated with risks of POD post-CAR-T and histological transformation warrant further study."

B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Oncology

ISOLATED CENTRAL NERVOUS SYSTEM RELAPSE AFTER CAR-T CELL INFUSION IN LARGE B-CELL LYMPHOMAS: AN ANALYSIS FROM THE ITALIAN CART-SIE STUDY (ICML 2025) - "Clinical characteristics were: median age 61 (IQR 53; 67); 80% DLBCL and 20% HGBCL; 74% were refractory; 76% had advanced stage III-IV; 57% received axicabtagene ciloleucel (axi-cel) and 43% tisagenlecleucel (tisa-cel). In the CART-SIE study, at a median follow-up of 17.93 months, 2% of LBCL patients had a CNS relapse. The cumulative incidence of CNS relapse at 2-year was 4.1%, that is lower than expected in a high-risk population. A longer follow-up is needed to confirm the impact of CAR-T cell in reducing the risk of CNS relapse."

CAR T-Cell Therapy • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Indolent Lymphoma • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Matching-adjusted indirect comparison (MAIC) of lisocabtagene maraleucel (liso-cel) versus axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) for treatment of third-line or later (3L+) R/R follicular lymphoma (FL): Update with 24 months of liso-cel follow-up (FU). (ASCO 2025) - P2 | "After incorporating longer FU data and adjusting for population differences, liso‑cel had a higher CR rate versus axi-cel and tisa-cel, and comparable or numerically favorable ORR, DOR, PFS, OS, and TTNT. Liso-cel had a more favorable safety profile versus axi-cel and a similar safety profile compared with tisa-cel."

Follicular Lymphoma • Hematological Malignancies • Lymphoma • Oncology

Venous thromboembolism among cancer patients receiving chimeric antigen receptor-T cell therapy. (ASCO 2025) - "Eligibility included administration of any one of the six CAR-T therapies (Tisagenlecleucel, Axicabtagene (Axi-cel), Brexucabtagene, Lisocabtagene, Idecabtagene and Ciltacabtagene) at age ≥18y...The use of glucocorticoids (95% vs 77%, P<0.0001), alkylating agents (91% vs 71%, P<0.0001) or lenalidomide (18% vs 11%, P=0.0006) were significantly associated with VTE... There is 10% incidence of VTE within three months of CAR-T therapy. Particularly, VTE incidence is higher with Axi-cel, and DLBCL diagnosis. Patients with high –risk associations may benefit from thromboprophylaxis regimens, particularly during initial three months of CAR-T therapy."

CAR T-Cell Therapy • Clinical • B Cell Lymphoma • Cardiovascular • Diffuse Large B Cell Lymphoma • Dyslipidemia • Genetic Disorders • Hematological Malignancies • Hypertension • Ischemic stroke • Lymphoma • Mantle Cell Lymphoma • Nicotine Addiction • Non-Hodgkin’s Lymphoma • Obesity • Oncology • Respiratory Diseases • Venous Thromboembolism

THREE-YEAR REAL-WORLD MORTALITY ANALYSIS OF CAR-T THERAPIES: TISA-CEL, AXI-CEL, AND LISO-CEL (EHA 2025) - "This large-scale real-world study provides valuable insights into mortality rates associated with three approved CAR-T therapies for refractory lymphomas over a three-year period. While mortality rates varied among therapies at different time points, survival analysis of DLBCL patients revealed no statistically significant differences in overall survival outcomes. These findings indicate consistent survival outcomes in real-world settings as observed in pivotal clinical trials."

Clinical • Real-world • Real-world evidence • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

CAR T-CELL THERAPY IS EFFICIENT IN VITREORETINAL LYMPHOMAS. A LOC NETWORK STUDY. (EHA 2025) - "Patients received either axicabtagene ciloleucel (N=4) or tisagenlecleucel (N=3). In conclusion, this study demonstrated for the first time the ability of CAR T-cells to migrate to the vitreoretinal space and to achieve a high rate of sustained complete responses in a small cohort of heavily pretreated VRL patients. Further studies and extended follow-up will help to better define the role of CAR T-cells in the therapeutic landscape of VRL."

CAR T-Cell Therapy • B Cell Lymphoma • CNS Disorders • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Epilepsy • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Ophthalmology

OUTCOMES OF CAR T-CELL THERAPY IN TRANSFORMED INDOLENT NON-HODGKIN LYMPHOMAS AND DE NOVO DLBCL: A COMPARATIVE ANALYSIS FROM THE ITALIAN CAR T-SIE STUDY (ICML 2025) - " A multicenter, observational, prospective study was conducted using the Italian CART-SIE study, including patients with R/R TiNHL and R/R dnDLBCL treated with commercial anti-CD19 CAR T-cell therapy (axi-cel or tisa-cel) between September 2019 and April 2024. This large real-world analysis demonstrates that patients with TiNHL treated with CAR T-cell therapy achieve superior outcomes compared to those with dnDLBCL, with a comparable safety profile. These findings support CAR T-cell therapy as an effective treatment option for TiNHL, warranting consideration as a standard approach in their treatment algorithm."

CAR T-Cell Therapy • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

CAR T-CELL THERAPY IS HIGHLY EFFECTIVE IN VITREORETINAL LYMPHOMAS. A LOC NETWORK STUDY (ICML 2025) - "Patients received either axicabtagene ciloleucel (N = 4) or tisagenlecleucel (N = 3). In conclusion, this study demonstrates, for the first time, the ability of CAR T-cells to migrate to the vitreoretinal space and to achieve a high rate of sustained complete responses in heavily pretreated VRL patients. Further studies and extended follow-up will help to better define the role of CAR T-cells in the therapeutic landscape of VRL."

CAR T-Cell Therapy • B Cell Lymphoma • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Oncology

BRIDGING RADIOTHERAPY DOES NOT INCREASE RISK OF CAR T-CELL ASSOCIATED TOXICITY (ICML 2025) - "Patients received axicabtagene (38%), lisocabtagene (33%), tisagenlecleucel (15%), brexucabtagene (3%), or an investigational agent (11%). BRT does not appear to increase CRS or ICANS after CAR-T compared to historic controls. Extent of disease (evidenced by high residual LDH) prior to CAR-T may be a more important driver of toxicity, emphasizing the benefit of cytoreduction. Patients treated to higher BEDs saw lower toxicity suggesting that effective cytoreduction outweighs any theoretical risk of radiation-associated inflammation."

CAR T-Cell Therapy • B Cell Lymphoma • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma

ANTI-CD19 CAR-T CELL THERAPY IN RELAPSED/REFRACTORY T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA: INSIGHTS FROM THE FRENCH DESCAR-T REGISTRY, A LYSA STUDY (ICML 2025) - "All patients underwent lymphodepletion with fludarabine and cyclophosphamide, followed by axicabtagene ciloleucel (n = 14), tisagenlecleucel (n = 8), or lisocabtagene maraleucel (n = 1)...Among R/R patients after CAR-T cell therapy, 7 remained alive at one year, having received lenalidomide and anti-CD20 mAb (n = 3), lenalidomide, ibrutinib and anti-CD20 mAb (n = 1), immune checkpoint inhibitors (ICIs) and autologous stem cell transplant (n = 1), ICIs alone (n = 1) or a bispecific anti-CD20/CD3 mAb (n = 1). Despite an overall low response rate, R/R THRLBCL patients achieving CR after anti-CD19 CAR-T cell therapy appeared to experience prolonged response durations."

CAR T-Cell Therapy • B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • T Cell Histiocyte Rich Large B Cell Lymphoma

OUTCOMES OF CAR T-CELL THERAPY VERSUS AUTOLOGOUS HSCT IN PATIENTS WITH LARGE B-CELL LYMPHOMA IN COMPLETE REMISSION: AN ANALYSIS FROM THE EBMT LYMPHOMA WORKING PARTY (ICML 2025) - " Among 2,732 patients, 189 received CAR T-cell therapy (108 axicabtagene ciloleucel (axi-cel), 80 tisagenlecleucel, 1 lisocabtagene maraleucel), and 2543 underwent auto-HSCT. Auto-HSCT remains a valid treatment option for selected fit, transplant-eligible LBCL patients achieving CR after salvage therapy. While improving access to CAR T-cell therapy should remain a priority, discussing the possibility of auto-HSCT in this specific subset of patients seems reasonable."

CAR T-Cell Therapy • Clinical • B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Outpatient administration of CAR T-cell therapy: A University of Arizona Cancer Center experience. (ASCO 2025) - "Methods to implement this in an outpatient setting have included early CRS (cytokine release syndrome) intervention with tocilizumab and multidisciplinary support including patient access to healthcare providers 24 hours a day (2-4)...CAR T-cell products administered included axicabtagene ciloleucel (n = 2, 5.1%), tisagenlecleucel (n = 28, 71.8%), and ciltacabtagene autoleucel (n = 9, 23.1%)...Among these, 62% (8) were treated with steroids, and 23% (3) received Anakinra... Our study shows CAR T-cell therapy can be safely administered in the outpatient setting with close monitoring, reducing inpatient LOS significantly."

CAR T-Cell Therapy • Clinical • B Cell Lymphoma • CNS Disorders • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Hypotension • Infectious Disease • Leukemia • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology • Plasma Cell Leukemia

OUTCOMES WITH CAR-T IN PATIENTS WITH T CELL HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA, UK EXPERIENCE (EHA 2025) - "We analysed 33 consecutive patients with THRBCL either de novo or transformed from NLPHL who were approved for treatment with axicabtagene ciloleucel (axi-cel) or tisagenlecleucel (tisa-cel) between Dec 2018 and Nov 2024 across UK CAR-T centres. THRBCL is associated with inferior outcomes to DLBCL with CAR-T with the majority of patients either refractory or developing early relapses. In contrast to previously reported case series of outcomes of patients with THRBCL, all patients in this cohort received bridging therapy prior to CAR-T delivery, however outcomes remain significantly inferior when compared to de novo DLBCL etiher in trials or real world setting wtih only 17% of patients remaining progression free and alive at 1year. However, there are rare cases of long-term responses and therefore until further is known as to potential predictors of response, CAR-T shouldn't be excluded as a potential treatment option, especially in those with chemosensitive disease..."

Clinical • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Large B Cell Lymphoma • Lymphoma • Nodular Lymphocyte Predominant Hodgkin Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • T Cell Histiocyte Rich Large B Cell Lymphoma

SERUM AND DEEP-LEARNING-BASED MRI BIOMARKERS OF NEUROTOXICITY AND SURVIVAL IMPLICATIONS AFTER CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN NON-HODGKIN LYMPHOMA (ICML 2025) - "Most received axi-cel (73%; 13 tisa-cel, 7 brexu-cel, 19 liso-cel). We demonstrate a novel application of DL-based MRI as a potential biomarker for ICANS post-CAR-T in NHL. These metrics may provide quantitative insight into neurotoxicity and its impact on survival outcomes. These findings warrant further prospective validation to refine the phenotype of patients at risk for ICANS and its prognostic significance."

Biomarker • CAR T-Cell Therapy • IO biomarker • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Oncology